23
Sep
2019
Tag: business development
2
Sep
2019
Bionest
Zolgensma Launch “On Track,” but Significant Challenges Remain
On July 18, Novartis told analysts its Zolgensma launch was “on track.” Despite the gene therapy’s $2.1 million price tag, the company states the launch is “one of the most successful launches from an access standpoint in rare diseases.” Novartis said it had reached coverage deals with more than 20 commercial insurance plans, covering approximately 40%...
26
Aug
2019
Bionest
The Rise of the Chief Digital Officer in Pharma Companies
Chief Digital Officer (CDO) is the latest title to become a standard within the pharmaceutical company C-suite, with Takeda, Bayer, GlaxoSmithKline, Novartis, Merck, Sanofi and others all making such appointments in recent years. As we’ve written before, this addition to the pharma senior management team reflects the growing importance of digital to pharma, which encompasses...
25
Mar
2019
Bionest
The Changing World of Medical Marketing
A recent survey published in the Journal of the American Medical Association (JAMA) reported that the medical marketing spend in the United States rose from approximately $17.7 billion in 1997 to just under $30 billion in 2016. The biggest growth came from Direct-to-Consumer (DTC) marketing, which increased from 11.9% to 32% of the total spend....
21
Jan
2019
Bionest
Big Oncology Mergers Kick Off 2019
Each January, a large portion of the international healthcare industry descends on San Francisco for the JP Morgan Healthcare Conference and a variety of other concurrent industry events. The sentiment of the nearly 10,000 attendees — largely influenced by partnering news and big merger/acquisition deals announced around these events — typically sets the tone for...
15
Jan
2019
Bionest
Differentiation Through Digital
Digital technology is becoming increasingly important in the healthcare space. This was clearly reflected by the growing number of companies and events focused on the digital healthcare sector during JP Morgan/Biotech Week in San Francisco and new conferences dedicated to digital technology applications in health and wellness that have been scheduled for 2019. Uses of...
2
Jan
2019
Bionest
Happy New Year — Some Thoughts on the Year to Come
Welcome to 2019. We hope you enjoyed the holidays and look forward to meeting and greeting many of you next week in San Francisco for Biotech Week. Several members of the Bionest team will be in attendance, and if you’d like to get together, we look forward to hearing from you. Last year, we...
24
Sep
2018
Bionest
U.S. Drug Spending: Where the Money Goes
Two recently published analyses are providing a more in-depth picture of prescription drug spending in the United States. Such evaluations illustrate the complexities facing policy makers and regulators seeking to help reduce patient and payer drug costs. In addition, they point to somewhat hidden issues regarding the pricing and reimbursement of generic drugs that can...
17
Apr
2018
Bionest
Moving from Exploratory Collaborations to Record-Setting Deals in IO
In early March, we wrote about the collaboration between Bristol-Myers Squibb and Nektar aimed at developing Nektar’s T-cell stimulating molecule NKTR-214 in combination with BMS’s checkpoint inhibitor Opdivo (nivolumab). That deal brought Nektar an eye-opening $1.85 billion in upfront cash and investments for a share of its development-stage drug, with the potential for an additional...
11
Apr
2018